Unhedged cover image

Novo Nordisk, Eli Lilly and the GLP-1 economy

Unhedged

00:00

Intro

This chapter explores the projected market growth and transformative effects of GLP-1 weight loss drugs on obesity treatment. It discusses the skepticism surrounding the hype, their implications for health systems and insurance, as well as current usage and challenges such as side effects.

Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner